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control, toxicity rates and survivals were evaluated in 
patients affected by inoperable advanced stage NSCLC who 
received hypofractionated radiotherapy. 
Materials and Methods: Seventy-two patients with advanced 
NSCLC were enrolled: 20 patients had stage IIIA, 36 patients 
had stage IIIB, and 16 had stage IV disease. Stage IV patients 
presented with ≤ 2 metastatic sites and stable disease. There 
were no restrictions on previous chemotherapy regimens. All 
patients underwent curative HypoRT with total dose 
prescribed 60 Gy in 20 fractions of 3Gy/each. Radiation 
treatment was delivered using an IGRT (Image-Guided 
Radiotherapy) technique to verify correct position. Toxicities 
were graded according to the RTOG morbidity score. 
Survivals were estimated using the Kaplan–Meier method. 
Results: The median follow up was 13 months (range: 4-58 
months). All patients completed radiotherapy and received 
the total dose of 60 Gy to the primary tumor and positive 
lymph nodes (BED=79Gy). The overall response rate after 
radiotherapy was 83%. The 2-year overall survival and 
progression free-survival rates were 43% and 35%, 
respectively. Median time to progression was 12 months. The 
median survival was 20 months. The loco-regional control and 
the metastases-free survival at 2 –years were 52% and 43%, 
respectively. The treatment was well tolerated. Eleven 
patients developed grade 3 acute toxicities (5 pts esophagitis 
and 6 pts pneumonitis). Ten patients developed grade 3 late 
toxicities: 6 pts pneumonitis and 4 patients esophagitis. 
Conclusions: Hypofractionated curative radiotherapy is a 
feasible and well-tolerated treatment for patients with 
locally advanced non-small cell lung cancer. Randomized 
studies are needed to compare HypoRT to the conventional 
treatment.  
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Purpose/Objective: This retrospective study explores the 
impact of SBRT as an aggressive local treatment on the 
disease evolution and survival of patients with 
oligometastatic and locally advanced-unresectable NSCLC. 
Materials and Methods: 209 lesions (190 pulmonary and 19 
adrenal) were irradiated using SBRT between February'08-
March‘14. Among 121 patients treated (KPS ≥70) 86 (71%) 
were oligometastatic which according to our criteria implied 
the presence of ≤ 5 lung-only metastases or ≤ 3 if presented 
in extra-pulmonary sites also. 31 patients (26%) were with 
single metastasis while 55 (45%) with multiple. The primary 
unresectable NSCLC was also treated in 73 patients (60%). 
Histology was squamous carcinoma in 30% of patients, 
adenocarcinoma(ADC) in 48% and other histologies in 22%. 
The median diameter of the lung lesions was 2.5 cm (range 
0.3-8.8) and of the adrenal metastases 3.3 cm (range 1.5-
5.5). SBRT was delivered with VMAT by 6MV LINAC and 
planned by TPS with Montecarlo algorithm. Lung lesions were 
treated in breath hold with 3 dose levels depending on tumor 
site and size: 26 Gy in a single fraction (47%) prescribed to 
the 70% isodose, 36 Gy (28%) and 30 Gy (25%) in 3 fractions to 
the 80% isodose (BED10 to isocenter = 175, 112.5 and 84.4, 
respectively). The adrenal lesions were treated with 36 Gy in 
3 fractions prescribed to the 70% isodose (BED10 to isocenter 
= 143). Set-up and isocenter were assessed by CBCT. The 
response was evaluated after 60 days by CT and PET, and 
every 3 months subsequently. Toxicity was assessed by CTCAE 
score.  
Results:  
 
 
At 1 and 2 years local control rates were 94% and 83%, overall 
survival(OS) rates 77% and 53% and progression free survival 
41% and 23%, respectively (median F.U. 13.5 months, range 
2-78). All of 17 'in field' recurrences observed (16 in lungs and 
1 adrenal), 79% of which were confirmed at the second follow 
up, resulted being in response at the first follow up. The 
probability of local recurrence correlates with histological 
type, lesion diameter and BED10 value. 87% of 'in field' 
recurrences were squamous histological types while ADCs in 
13%. Only 6.7% of 120 lung lesions treated with BED10 > 100 
have relapsed while 19% of 42 treated with BED10 ≤ 100. In a 
subgroup of lesions with a diameter < 2 cm (66 lesions) only 1 
relapsed (1.5%). The probability of progression disease show 
a trend related to the time elapsed between the appearance 
of metastases and SBRT, > 2 lung metastases vs. ≤ 2, multi-
organic metastases vs. only in lung, and squamous histology 
vs. others. We didn’t observe toxicity > G2. 
Conclusions: SBRT for lung and adrenal lesions is a safe and 
effective ablative treatment using high BED10 values (> 100). 
Lower probability of local control is related to squamous 
histological type, lesion diameter > 2cm and BED10 ≤ 100. A 
better OS is correlated with non-squamous histology, shorter 
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time elapsed between metastasis appearance and SBRT, ≤ 2 
metastases and single-organ metastatic site. 
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Purpose/Objective: Literature data suggest that the 
oligometastatic state might exist in NSCLC. Selected patients 
with limited metastatic disease can achieve long-term 
survival when treated with locally ablative therapies as 
Stereotactic Ablative radiotherapy (SABR). 
The aim of this study is the evaluation of toxicity, local 
control and overall survival in NSCLC oligometastatic patients 
underwent SABR for lung lesions after multidisciplinary 
assessment. 
Materials and Methods: SABR was performed in 
oligometastatic patients with controlled primary tumor, long 
interval time from the first diagnoses (greater than 6-12 
months), adequate pulmonary function, and number of 
metastatic sites ≤ 5. All patients were discussed at 
multidisciplinary team. According to site and maximum 
diameter of the lung lesion, we adopted the following dose 
prescription: 60 Gy in 3 fractions for peripheral lesions with 
diameter ≤ 2 cm, 48 Gy in 4 fractions for peripheral lesions 
(diameter > 2cm and ≤ 5 cm) and 60 Gy in 8 fractions for 
central lesions. Radiological response was defined according 
to RECIST criteria. Toxicity was recorded according to the 
Common Toxicity Criteria (CTC) version 4.0. 
Results: Between October 2010 and March 2014, 65 NSCLC 
patients for 89 lung lesions were treated at our Institution. 
Radiological response was obtained in most of patients. No 
pulmonary toxicity G3-G4, chest pain or rib fracture 
occurred. The local control at 1 and 2 years was 98% and 87% 
respectively. The median follow up was 24 months (range 6-
40 months). Overall Survival (OS) at 1, 2 years was 77% and 
51% respectively. 
Conclusions: SABR is well tolerated with good radiological 
response and optimal toxicity profile. Discussion within a 
multidisciplinary team is crucial to identify the 
oligometastatic patients could really benefit from ablative 
local therapy.  
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Purpose/Objective: Daily low dose concurrent 
chemoradiation with cisplatin is the standard treatment in 
our institute for locally advanced non-small cell lung cancer 
(NSCLC). However, some patients experiencing renal toxicity 
are not able to receive all cisplatin gifts. Prior to 2011 only 
patients with a decline in renal function were therefore pre-
hydrated with saline prior to treatment in order to reduce 
this toxicity. Since 2011 daily pre-hydration (PH+) has become 
standard practice for all low-dose cisplatin chemoradiation 
patients treated for NSCLC. Renal toxicity is reduced as 
expected but unexpectedly grade 2 or higher acute 
oesophagus toxicity was also reduced from 62% to 34%1. This 
led us to question if there could also be an effect on the 
efficacy of the treatment. The aim of this study was 
therefore to evaluate the effect of pre-hydration on 
progression free survival (PFS) in NSCLC patients treated with 
daily low dose cisplatin chemoradiation. 
Materials and Methods: In total 418 locally advanced 
patients treated in the period 2007-2013 were included in 
this retrospective study. All patients received daily low dose 
cisplatin (6mg/m2). The patients were divided into two time 
periods; 2007-2010 without standard pre-hydration (PH-) and 
2011-2013 with PH+ (1 litre of saline 0.9% prior to the 
administration of a bolus injection of cisplatin). All patients 
received radiotherapy with a prescribed dose of 24 x 2.75 Gy, 
1-2hour after cisplatin injection. Patient and treatment 
characteristics were collected and evaluated. Median follow-
up, PFS and overall survival (OS) were analysed using the log-
rank test and Cox regression. 
Results: The median OS for PH- vs PH+ was 25 and 22 months, 
respectively (p=0.53) with a median follow up of 56 and 20 
months. The median PFS for PH- vs PH+ was 14 and 11 months 
respectively (p=0.11, see figure 1). There was, however, also 
a significant difference in the median GTV of 100 cc in the 
PH- and 61 cc in the PH+ groups (p<0.05). Therefore 
multivariate Cox regression analysis was performed, in which 
PH+ was associated with a hazard ratio (HR) of 1.24 (CI: 0.98-
1.58; p=0.08) and GTV with a HR=1.008 per 1 cc (CI: 1-1.016; 
p=0.06). 
Conclusions: Prehydration in NSCLC patients treated with 
daily low dose concurrent chemoradiation appears to reduce 
progression free survival. Further research into the effect of 
prehydration on cisplatin kinetics within the patient is 
required. This is currently being investigated in mouse 
models. 
1Uyterlinde et al.2014 . 
 
 
 
   
 
 
 
 
 
 
